Recommended

Register now: Enhancing biopharma workflows with the power of UV/Vis spectroscopy webinar
Download our brand new eBook: A practical guide to single-use filtration in biopharma.
Join us as we look at how the outsourcing of buffers is helping biopharma drug manufacturers to streamline their processes.
Discover more on how Polpharma API meets evolving regulatory guidance around N-nitrosamines control in APIs with Waters’ high-performance analysis instruments.
Learn more about leveraging real-world data, the practical applications of AI and adopting configurable LC/NC solutions.
Download this compendium to discover how hot-melt extrusion can help to overcome pharmaceutical formulation challenges
article

Manufacturing, Packaging & Logistics In-Depth Focus 2020

In this in-depth focus explore the implications of Trump’s ‘Buy American’ order for drug manufacturers, how researchers step-up metformin production from lab to industry scale and a discussion on how advanced planning could enable pharmaceutical production to be scaled up.

    To read this In-Depth Focus in full, please complete the form below:

     









    This specialist content is provided to you free-of-charge thanks to the kind support of Nemera

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.

    • How will Trump’s ‘Buy American’ executive order impact pharmaceutical supply chains?
      On 6 August 2020, US President Donald Trump signed an executive order, dubbed ‘Buy American’, with the aim of increasing the production of essential medicines in the US for domestic use. Here, Victoria Rees discusses the order and what it means for drug manufacturers in the US and rest of the world.
    • Stepping up metformin production: a case study
      This article describes how researchers stepped up metformin tablet production from a pilot scale coater to three industrial scale equipment lines.
    • Scaling up production capacity when the world is waiting
      As the race to develop a COVID-19 vaccine intensifies, nations are already ramping up production capacity on a scale never seen before – but what does this mean for manufacturers? Here, Rod Schregardus makes the case for advanced planning and scheduling techniques in new and existing facilities.